Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 2, 2017, Pages 213-220

  Puig, L ^a   Thom, H ^b   Mollon, P ^c   Tian, H ^c   Ramakrishna, G S ^d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Novartis Healthcare Private Limited   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BAYES THEOREM; CLEAR SKIN; CLINICAL EFFECTIVENESS; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITATIVE ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN; SYSTEMATIC REVIEW; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

HUMANS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84995572388     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.14007     Document Type: Review

References (31)

1. Baker EL, Coleman CI, Reinhart KM et al. Effect of biologic agents on non-PASI outcomes in moderate to severe plaque psoriasis: systematic review and meta-analyses. Dermatol Ther 2012; 2: 9.
2. Wakee M, Nijsten T. Comorbidities in dermatology. Dermatol Clin 2009; 27: 137–147.
3. Wahl A, Loge JH, Wiklund I, Hanestad BR. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 2000; 43: 803–808.
4. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol 1993; 32: 188–190.
5. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401–407.
6. Sampogna F, Tabolli S, Soderfeldt B, Axtelius B, Aparo U, Abeni D. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006; 154: 844–849.
7. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis. Arch Dermatol 2010; 146: 891–895.
8. Khalid JM, Globe G, Fox KM, Chau D, Maguire A, Chiou CF. Treatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort study. BMC Dermatol 2013; 13: 9.
9. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS ONE 2012; 7: e52935.
10. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence 2013; 7: 199–205.
11. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2014; 135: 1–8.
12. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496–509.
13. Roman M, Madkan VK, Chiu MW. Profile of secukinumab in the treatment of psoriasis: current perspectives. Ther Clin Risk Manag 2015; 11: 1767–1777.
14. Leman J, Burden A. Treatment of severe psoriasis with infliximab. Ther Clin Risk Manag 2008; 4: 1165–1176.
15. Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2015; 135: 2641–2648.
16. Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol 2015; 29: 645–648.
17. Torii H, Sato N, Yoshinari T, Nakagawa H. Japanese infliximab study I. dramatic impact of a psoriasis area and severity index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol 2012; 39: 253–259.
18. Finlay AY, Khan GK. Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216.
19. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659–664.
20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
21. Kalb RE, Blauvelt A, Sofen HL et al. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. J Drugs Dermatol 2013; 12: 874–880.
22. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis In Medical Research. John Wiley & Sons, London, 2000.
23. Welton NJ, Sutton AJ, Cooper N, Abrams KR, Ades AE. Evidence Synthesis for Decision Making in Healthcare. John Wiley and Sons, London, 2012.
24. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011. URL http://www.nicedsu.org.uk. (last accessed: 24 May 2016)
25. Speigelhalter DJ, Best NG, Carlin BP, Van der Linde A. Bayesian measures of model complexity and fit. JR Stat Soc B 2002; 64: 583–639. URL: https://classes.soe.ucsc.edu/ams207/Spring10/DIC.pdf (last accessed: 25 May 2016.)
26. Lunn DJ, Jackson CH, Best N, Thomas A, Spiegelhalter D. The BUGS Book: A Practical Introduction to Bayesian Analysis. CRC Press, New York, 2013.
27. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015; 73: 400–409.
28. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008; 216: 260–270.
29. Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira HD. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. J Drugs Dermatol 2014; 13: 554–562.
30. McLeod LD, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI 90 response achieve greater health-related quality-of-life improvements than those With PASI 75-89 Response. Presented at the European Association of Dermatology and Venereology Congress, Amsterdam, Netherlands (abstr.) 2014.
31. Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (pasi) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28: 333–337.